Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03119194
Recruitment Status : Completed
First Posted : April 18, 2017
Last Update Posted : August 24, 2017
Sponsor:
Information provided by (Responsible Party):
Bial - Portela C S.A.

Brief Summary:
The purpose is to and to assess the mass balance recovery after a single oral dose of [14C]-BIA 9-1067 and to provide plasma, urine and faecal samples for metabolite profiling and structural identification.

Condition or disease Intervention/treatment Phase
Parkinson Disease Drug: [14C]-BIA 9-1067 Phase 1

Detailed Description:

This is an open-label, single-dose, single-period, non-randomised study in healthy male subjects. Subjects will be screened for eligibility to participate in the study between 28 and 2 days before dosing. Eligible subjects will be admitted to the clinical unit on the evening of the day before dosing (Day -1). Subjects will be dosed on the morning of Day 1 following an overnight fast of approximately 8 h. Blood, urine, faeces and expired air will be collected at predefined time points for mass balance and PK analysis. Subjects will remain resident in the clinic until the morning of Day 22, when they will be discharged as a group.

Single dose administration on a single occasion. The estimated duration of the study from screening until the final return visit is approximately 3.5 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067 in Healthy Male Subjects
Actual Study Start Date : January 27, 2017
Actual Primary Completion Date : April 27, 2017
Actual Study Completion Date : April 27, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Reguimen A - [14C]-BIA 9-1067

100 mg [14C]-BIA 9-1067 Capsule containing not more than 3.3 MBq (89.2 µCi) 14C; will be administered with 240 mL water.

Single dose administration on a single occasion.

Drug: [14C]-BIA 9-1067
1 × 100 mg capsule, Oral




Primary Outcome Measures :
  1. Mass balance recovery of total radioactivity in all (urine, faeces and expired air combined) amount excreted (Ae) expressed as a percentage of the administered dose (%Ae) [ Time Frame: Urine and faeces: pre-dose,0,0.25,0.5,0.75,1,1.5, 2, 3, 4, 6,8,12,18,24,36,48,72,96,120,144,168,240,312,408,504,648 hours after dosing. Expired air: Pre-dose, 0.5,1,1.5,2,4,6,8,12,18,24,36,48,72,96,120,168,240,312,408,504 hours after dosing. ]
    Mass balance of total radioactivity in urine, faeces and expired air

  2. Mass balance recovery of total radioactivity in all (urine, faeces and expired air combined) cumulative recovery (CumAe) expressed as a percentage of the administered dose (Cum%Ae) [ Time Frame: Urine and faeces: pre-dose,0,0.25,0.5,0.75,1,1.5, 2, 3, 4, 6,8,12,18,24,36,48,72,96,120,144,168,240,312,408,504,648 hours after dosing. Expired air: Pre-dose, 0.5,1,1.5,2,4,6,8,12,18,24,36,48,72,96,120,168,240,312,408,504 hours after dosing. ]
    Mass balance of total radioactivity in urine, faeces and expired air


Secondary Outcome Measures :
  1. Tlag: the elapsed time from dosing at which analyte was first quantifiable in a concentration vs time profile [ Time Frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 240, 408, 504 hours after dosing ]
    Pharmacokinetic Data Analysis for BIA 9-1067 and its metabolites, BIA 9-1103 and BIA 9-4588

  2. Cmax: maximum observed concentration [ Time Frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 240, 408, 504 hours after dosing ]
    Pharmacokinetic Data Analysis for BIA 9-1067 and its metabolites, BIA 9-1103 and BIA 9-4588

  3. Tmax: the time from dosing at which Cmax was apparent [ Time Frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 240, 408, 504 hours after dosing ]
    Pharmacokinetic Data Analysis for BIA 9-1067 and its metabolites, BIA 9-1103 and BIA 9-4588

  4. AUC0-t: area under the curve from 0 time to last measurable concentration [ Time Frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 240, 408, 504 hours after dosing ]
    Pharmacokinetic Data Analysis for BIA 9-1067 and its metabolites, BIA 9-1103 and BIA 9-4588



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy males;
  • Age 30 to 65 years of age;
  • Body mass index of 18.0 to 35.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator;
  • Normal resting supine blood pressure and pulse or showing no clinically relevant deviation as judged by the investigator;
  • Computerized (12-lead) ECG recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the investigator;
  • All values for clinical laboratory tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the investigator;
  • Must be willing and able to communicate and participate in the whole study;
  • Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day);
  • Must provide written informed consent;
  • Must agree to use an adequate method of contraception

Exclusion Criteria:

  • Females;
  • Subjects who have received any IMP in a clinical research study within the previous 3 months;
  • Subjects who are study site employees, or immediate family members of a study site or sponsor employee;
  • Subjects who have previously been enrolled in this study;
  • History of any drug or alcohol abuse in the past 2 years;
  • Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine);
  • Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening and admission;
  • Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
  • Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study;
  • Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening;
  • Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator;
  • Positive drugs of abuse test result;
  • Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results;
  • Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance of <90 mL/min using the Cockcroft-Gault equation;
  • History of cardiovascular, neurological, renal, hepatic, chronic respiratory or gastrointestinal disease, or clinically significant psychiatric history as judged by the investigator;
  • Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
  • Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active;
  • Donation or loss of greater than 400 mL of blood within the previous 3 months;
  • Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 2 g per day paracetamol) or herbal remedies in the 14 days before IMP administration. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the PI and sponsor's medical monitor;
  • Failure to satisfy the investigator of fitness to participate for any other reason.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03119194


Locations
Layout table for location information
United Kingdom
Quotient Clinical
Ruddington, Nottingham, United Kingdom, NG11 6JS
Sponsors and Collaborators
Bial - Portela C S.A.
Layout table for additonal information
Responsible Party: Bial - Portela C S.A.
ClinicalTrials.gov Identifier: NCT03119194    
Other Study ID Numbers: BIA-91067-130
First Posted: April 18, 2017    Key Record Dates
Last Update Posted: August 24, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Opicapone
Catechol O-Methyltransferase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antiparkinson Agents
Anti-Dyskinesia Agents